NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene ...

This is a video synopsis/summary of an Insights involving Allison Wheeler, MD. Wheeler addresses the nuanced considerations for implementing prophylaxis in patients with mild to moderate hemophilia A, ...

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody significantly reduced both treated spontaneous and traumatic bleeds among individuals ...

Please provide your email address to receive an email when new articles are posted on . Patients who received prophylactic concizumab had a mean overall annualized bleeding rate of zero compared with ...

The MarketWatch News Department was not involved in the creation of this content. -- New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from ...

Methods We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses ...

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment Once-weekly efanesoctocog alfa met primary ...

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...

An antisense oligonucleotide therapy showed efficacy as a prophylactic treatment for hereditary angioedema (HAE), the phase III OASIS-HAE trial showed. The least-squares mean time-normalized HAE ...

The urinary antiseptic methenamine hippurate (Hiprex) was non-inferior to antibiotic prophylaxis in women with a history of recurrent urinary tract infections (UTI), according to results from the ...